Effect of Pre-operative Depo Medroxyprogesterone Acetate on Serum Anti-mullerian Hormone Level After Laparoscopic Ovarian Cystectomy of Endometriomas

Mahidol University40 enrolled

Overview

The purpose of this study is to evaluate the ovarian reserve changes after preoperative depot medroxyprogesterone acetate (DMPA) in women with ovarian endometrioma undergoing laparoscopic cystectomy.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Endometriosis

Interventions

depot medroxyprogesterone acetateDRUG

DMPA 150 mg intramuscular Before surgery 3 months (plus or minus 2 weeks)

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy women 18-40 years old * A diagnosis of endometrioma with diameter of at least 3 cm. * Candidates for laparoscopic cystectomy Exclusion Criteria: * Patients' refusal to participate * Not candidate for depot medroxyprogesterone acetate such as: cirrhosis, chronic kidney disease, venous thrombosis * Use of estrogen-suppressive drugs in the preceding 3 months, such as: Oral contraceptives, GnRH analogues, Progestins, Danazol * Pathology report present no endometriosis

Locations (1)

Department of Obstetrics and Gynecology

Ratchathewi, Bangkok, Thailand

Outcomes

Primary Outcomes

Percentage Changes of Serum Anti-Mullerian Hormone (AMH) at 2-week and 3-month Post Operation

Time frame: Within the first 2 weeks and 3 months after surgery

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.